Metabolism Clinical Trial
Official title:
(KIWI) Speeding up a Slow Protein for Muscle Mass With Hay Kiwifruit
NCT number | NCT04356573 |
Other study ID # | 206814 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2018 |
Est. completion date | November 20, 2018 |
Verified date | October 2021 |
Source | University of Arkansas |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The specific hypothesis is that the consumption of 2 Hayward green kiwifruit (containing actinidin protease) prior to 100g of ground beef will increase the rate of protein digestion from the beef in the elderly, leading to an increased uptake of the essential amino acids. Furthermore, this increased essential amino acid availability will produce a greater postprandial net anabolic protein response, as well as increased fractional synthetic rates of muscle proteins.
Status | Completed |
Enrollment | 13 |
Est. completion date | November 20, 2018 |
Est. primary completion date | November 20, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility | Inclusion Criteria: - men and women ages 60-85 inclusive. Exclusion Criteria: - Inability to chew meats or difficulty swallowing solid foods - History of diabetes - History of malignancy in the 6 months prior to enrolment - History of gastrointestinal reduction or bypass surgery (Lapband, etc) - History of a chronic inflammatory condition or disease (Lupus, HIV'AIDS, etc) - History of chronic kidney disease or currently requiring dialysis. - Allergy to beef or kiwifruit - Subjects who do not or will not eat animal proteins - Subjects who cannot refrain from consuming protein or amino acid supplements during their participation in this study - Subjects who report regular resistance exercise (more than once per week) - Hemoglobin less than 9.5mg/dL at the screening visit - Platelets less than <150,000 at the screening visit - Subjects who are not willing or able to suspend aspirin for several days prior to their muscle biopsies. - Subjects who have been prescribed a blood-thinning medication (Coumadin, lovenox, heparin, Plavix, etc). - Concomitant use of corticosteroids (ingestion, injection or transdermal) - Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician |
Country | Name | City | State |
---|---|---|---|
United States | UAMS Center on Aging | Little Rock | Arkansas |
Lead Sponsor | Collaborator |
---|---|
University of Arkansas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Whole Body Net Balance Measured by Gas Chromatography-Mass Spectrometry (GC-MS) | Blood samples were analyzed to quantify the appearance of the stable isotopes: 2H2-tyrosine, 2H4-tyrosine, and 2H5-phenylalanine in tracer to tracee ratio or mole percent excess. Changes in these markers over time enable the calculation of whole body protein metabolism. Calculations are done as follows:
Total plasma rate of appearance = infusion rate/enrichment Fractional rate of appearance of tyrosine from phenylalanine= 2H4-tyrosine/2H5-phenylalanine Phenylalanine hydroxylation = fractional rate of appearance of tyrosine from phenylalanine x rate of appearance of tyrosine Protein Synthesis = [(rate of appearance of phenylalanine -Phe hydroxylation) x 25] Protein Breakdown = [(rate of appearance of phenylalanine - phenylalanine infusion rate) x 25 - phenylalanine intake] Net Balance = Protein Synthesis - Protein Breakdown |
300 minutes | |
Secondary | Change in Skeletal Muscle Protein Metabolism Measured by Gas Chromatography-Mass Spectrometry (GC-MS) | Muscle samples were analyzed to quantify the appearance of the stable isotope 2H5-phenylalanine in trace to tracee ratio or mole percent excess. The change in 2H5-phenylalanine in subsequent muscle biopsy allow for the calculation of muscle protein synthesis. The calculation is done as follows: [(2H5-phenylalanine enrichment in second biopsy - 2H5-phenylalanine enrichment in second biopsy)/ (2H5-phenylalanine plasma enrichment × time)] × 60 × 100. | 9.5 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00070577 -
Influence of Age and Sex on Alcohol Metabolism and Acute Responses
|
N/A | |
Active, not recruiting |
NCT05488574 -
Effects of Novel Breathing Behavior Modification Yoga Positioning Integrated Program on Weight Loss
|
N/A | |
Recruiting |
NCT05582824 -
Lactate Metabolism in the Hypoperfused Critically Ill
|
||
Recruiting |
NCT05443347 -
Activity, Adiposity, and Appetite in Adolescents 2 Intervention
|
N/A | |
Completed |
NCT05020808 -
The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest and After Resistance Exercise
|
N/A | |
Recruiting |
NCT06082726 -
The Systemic Concentration of Short-Chain Fatty Acids After Delivery in the Small and Large Intestine of Healthy Volunteers
|
N/A | |
Completed |
NCT04144426 -
Meal Schedule Effects on Circadian Energy Balance in Adults
|
N/A | |
Completed |
NCT03424395 -
Personalized Dietary Program and Markers of Wellness
|
N/A | |
Completed |
NCT02441296 -
Carbohydrate and Metabolism: a Pilot Study
|
N/A | |
Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 | |
Completed |
NCT00245986 -
Effect of Genetics on Metabolism of Efavirenz
|
Phase 4 | |
Completed |
NCT04025346 -
To Evaluate the Efficacy of Capsimax on Metabolic Rate
|
N/A | |
Completed |
NCT04078646 -
Influence of Proteins on the Bioavailability of Carotenoids
|
N/A | |
Active, not recruiting |
NCT06033898 -
Inactivity Duration on Lipid Metabolism
|
N/A | |
Active, not recruiting |
NCT06250270 -
Effects of Casein Protein on Metabolism When Taken Prior to Sleep and in the Morning
|
Early Phase 1 | |
Completed |
NCT06285578 -
Effects of Probiotic and HIIT in Obese Women
|
N/A | |
Completed |
NCT04255368 -
Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response
|
N/A | |
Recruiting |
NCT06360796 -
Study of Pharmacokinetics and Metabolism on [(14)C]ADC189
|
Phase 1 | |
Recruiting |
NCT02005003 -
Cognitive and Metabolic Effects of a Probiotic Supplement
|
N/A | |
Completed |
NCT03146728 -
Finding the Optimal Voluntary Exercise Parameters for Those Living With Quadriplegia
|
N/A |